Cellid Co. Ltd - Asset Resilience Ratio

Latest as of December 2025: 0.04%

Cellid Co. Ltd (299660) has an Asset Resilience Ratio of 0.04% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check asset allocation strategy of Cellid Co. Ltd to assess the company's strategic physical and investment asset allocation.

Liquid Assets

₩45.00 Million

≈ $30.50K USD Cash + Short-term Investments

Total Assets

₩110.87 Billion

≈ $75.13 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2016–2025)

This chart shows how Cellid Co. Ltd's Asset Resilience Ratio has changed over time. See how leveraged is Cellid Co. Ltd's balance sheet to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Cellid Co. Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Cellid Co. Ltd market capitalisation.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	₩0.00	0%
Short-term Investments	₩45.00 Million	0.04%
Total Liquid Assets	₩45.00 Million	0.04%

Asset Resilience Insights

Limited Liquidity: Cellid Co. Ltd maintains only 0.04% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

Cellid Co. Ltd Industry Peers by Asset Resilience Ratio

Compare Cellid Co. Ltd's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Ascendis Pharma AS NASDAQ:ASND	Biotechnology	0.00%
Biomarin Pharmaceutical Inc NASDAQ:BMRN	Biotechnology	0.00%
Spyre Therapeutics Inc. NASDAQ:SYRE	Biotechnology	84.34%
3SBio Inc F:83B	Biotechnology	10.64%
Soleno Therapeutics Inc NASDAQ:SLNO	Biotechnology	20.15%
Jiangxi Fushine Pharmaceutical Co Ltd SHE:300497	Biotechnology	0.02%
Novavax Inc NASDAQ:NVAX	Biotechnology	53.87%
BB Biotech AG SW:BION	Biotechnology	0.05%

Annual Asset Resilience Ratio for Cellid Co. Ltd (2016–2025)

The table below shows the annual Asset Resilience Ratio data for Cellid Co. Ltd.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	0.04%	₩45.00 Million ≈ $30.50K	₩110.87 Billion ≈ $75.13 Million	-11.87pp
2024-12-31	11.91%	₩9.06 Billion ≈ $6.14 Million	₩76.09 Billion ≈ $51.56 Million	-11.59pp
2023-12-31	23.50%	₩15.02 Billion ≈ $10.18 Million	₩63.92 Billion ≈ $43.32 Million	-17.24pp
2022-12-31	40.74%	₩18.68 Billion ≈ $12.66 Million	₩45.86 Billion ≈ $31.08 Million	+6.52pp
2021-12-31	34.23%	₩19.94 Billion ≈ $13.51 Million	₩58.26 Billion ≈ $39.48 Million	+9.79pp
2020-12-31	24.43%	₩12.07 Billion ≈ $8.18 Million	₩49.40 Billion ≈ $33.48 Million	+21.38pp
2019-12-31	3.05%	₩1.60 Billion ≈ $1.08 Million	₩52.52 Billion ≈ $35.59 Million	-52.42pp
2018-12-31	55.47%	₩7.89 Billion ≈ $5.34 Million	₩14.22 Billion ≈ $9.63 Million	-35.40pp
2017-12-31	90.86%	₩4.51 Billion ≈ $3.06 Million	₩4.96 Billion ≈ $3.36 Million	+4.43pp
2016-12-31	86.44%	₩3.29 Billion ≈ $2.23 Million	₩3.81 Billion ≈ $2.58 Million	--

pp = percentage points

About Cellid Co. Ltd

KQ:299660 Korea Biotechnology

Market Cap

$52.38 Million

₩77.30 Billion KRW

Market Cap Rank

#21790 Global

#1303 in Korea

Share Price

₩2620.00

Change (1 day)

-3.14%

52-Week Range

₩2315.00 - ₩5690.00

All Time High

₩127128.20